DIABETES
Diabetes mellitus (DM) is a disease of inadequate control of glucose in the blood. The main subtypes of DM are Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM), which classically result from defective insulin secretion (T1DM) and/or in its action (T2DM). In the case of DM, insulin is either absent and/or has impaired action (insulin resistance), and thus leads to hyperglycemia or high glucose levels.
T1DM is characterized by the destruction of beta cells in the pancreas and consequentially, insulin is either absent or extremely low. T2DM involves a more insidious onset where an imbalance between insulin levels and insulin sensitivity causes a functional deficit of insulin. Insulin resistance is multifactorial but commonly develops from obesity and aging.
INSULIN AND ITS USAGE
T2DM involves a more insidious onset where an imbalance between insulin levels and insulin sensitivity causes a functional deficit of insulin. Insulin resistance is multifactorial but commonly develops from obesity and aging.
Dedicated Research
Over two decades of continuous and dedicated research resulted in a delivery platform to administer Insulin and various other biological molecules either through Oral or Nasal route. Number of studies done till date suggest, efficacy of this technology to be far superior and result oriented.
‘Nozulin’ or ‘TrabiORAL’ is to be available as a Nasal or Oral spray of Insulin removing the inconvenience faced due to repeated injections hence, contributes to better compliance in managing diabetes in persons of all ages by administering Insulin without fear or hesitation, a boon for all diabetics Type I or II.
Nozulin or TrabiORAL is administered through a simple device to administer human Insulin made up of nano-particles to help patients achieve good blood sugar control.
‘Nozulin’ or ‘TrabiORAL’ is a rapid-acting, insulin nasal spray to control high blood sugar in type 1 or type 2 diabetes. Our Nozulin or TrabiORAL Insulin has already been tested in a number of studies to arrive at an optimized formulation to move towards commercialization during 2024-25. The results of various studies demonstrate its uniqueness in rapid onset of action and high bio-availability comparable to SC route of administration.
Beyond rapid acting Insulin, Niedlfree has also demonstrated the efficacy and high bi-availability of other GLP-1 peptides such as Exenatide and Liraglutide